Posted on 02/02/2012 5:23:48 AM PST by NYer
In addition to stopping funding for the Planned Parenthood abortion business, Komen for the Cure has also quietly stopped funding embryonic stem cell research centers, another concern for pro-life advocates.
As LifeNews reported last July, Karen Malec of the Coalition on Abortion/Breast Cancer spent time examining Komen’s 990 Forms for the IRS for 2010 and she found that Komen has active relationships with at least five research groups or educational facilities that engage in embryonic stem cell research, which requires the destruction of unborn children in their earliest days for stem cells that have yet to help any patients.
The return showed donations from Komen totaling $3.75 million to Johns Hopkins University School of Medicine, $4.5 million to the University of Kansas Medical Center, $1 million to the U.S. National Cancer Institute, $1 million to the Society for Women’s Health Research, and $600,000 to Yale University. All of them have embryonic stem cell research programs.
On November 30, 2011, Komen quietly added a new statement to its web site stating that it does not support embryonic stem cell research but supports the kinds that do not involve the destruction of human life.
“Komen supports research on the isolation, derivation, production, and testing of stem cells that are capable of producing all or almost all of the cell types of the developing body and may result in improved understanding of or treatments for breast cancer, but are derived without creating a human embryo or destroying a human embryo,” Komen says. “A priority in our research funding is to quickly find and deliver effective treatments, especially for the most lethal forms of breast cancer, while seeking effective preventive strategies, enhanced screening methodologies, and solutions to disparities in breast cancer outcomes for diverse women.”
Related Links
Komen, in its listing of grants for 2011, lists two stem cell studies that do not involve the use of embryonic stem cells.
LifeNews talked with pro-life sources close to the Komen situation who confirmed Komen will categorically not fund any embryonic stem cell research and the purpose of the November 2011 statement is to inform grant seekers that Komen will not do so.
Komen’s funding for embryonic stem cell research centers was an issue for pro-life advocates. Recent statements from the Catholic Bishop of Toledo, the Most Reverend Leonard Blair, bring up both abortion and the potential of Komen indirectly supporting embryonic research as reasons for Catholics to have misgivings about the breast cancer group.
“They are open to embryonic stem cell research and may well fund such research in the future,” the bishop noted.
Meanwhile, as LifeNews reported, new Komen Vice President for public policy Karen Handel, a pro-life advocate for Georgia, also opposes embryonic stem cell research. She has been credited with being instrumental in helping stop the Planned Parenthood funding.
“I oppose embryonic stem cell research, which creates life solely for the purpose of destroying it. I do, however, strongly support adult stem cell research, which has produced numerous scientific achievements without terminating innocent lives in the process,” Handel said in 2010 as a candidate for the U.S. Senate.
Although there has been some debate in the past about the link between abortion (also called induced abortion) and breast cancer risk, research clearly shows no link between the two [450]. Since 2003, the Board of Scientific Advisors and Board of Scientific Counselors of the National Cancer Institute (NCI), as well as the American College of Obstetricians and Gynecologists, have agreed the scientific evidence does not support a link between abortion and breast cancer [451-452]. The NCI routinely reviews the evidence on this topic and continues to agree the evidence does not support a link between the two [453].
The importance of study design for research on abortion and breast cancer risk
Some case-control studies have suggested abortion may increase the risk of breast cancer [454]. However, the nature of case-control studies makes the accuracy of their results questionable.
Case-control studies rely on the reporting of past behavior. When it comes to a sensitive topic like abortion, this can have a big impact on the information gathered. The cases in these studies (the women with breast cancer) may be much more likely to give complete information about their abortion history than the controls (the women without breast cancer). Such differences in reporting can bias study results.
Prospective cohort studies are much more likely to give accurate results on the topic of abortion. These studies gather sensitive information before women are diagnosed with breast cancer. This helps limit biased reporting. The results from cohort studies show abortion does not increase the risk of breast cancer [451,455-462].
Until they admit that there is at least a possible correlation or link I will still not support them.
That is great to hear. I’m going to send Komen a donation—it should be rewarded for dropping its affiliations with the abortionist Planned Parenthood and embryo-destroying research.
Freepmail wagglebee to subscribe or unsubscribe from the moral absolutes ping list.
FreeRepublic moral absolutes keyword search
Great, Komen is stopping embryonic stem cell research, too. I wonder how many people knew they were into that form of cannibalism as well? Goes claw in claw with abortion and IVF.
Ditto! In fact, I would take it to the next level and include artificial contraceptives and abortion. It doesn't take a ton of costly research to see the growth in breast cancer among women on artificial birth control.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.